Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options

@article{Thase2006PreventingRA,
  title={Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options},
  author={Michael E. Thase},
  journal={CNS Spectrums},
  year={2006},
  volume={11},
  pages={12 - 21}
}
  • M. Thase
  • Published 2006
  • Medicine
  • CNS Spectrums
Abstract Depression is increasingly recognized as a highly recurrent and potentially chronic illness that imposes a substantial burden on individuals, families, and society. Evidence indicates that the risks of depressive recurrence, treatment resistance, and chronicity increase as the illness becomes more highly recurrent. Up to 1 year of continuation phase therapy is now recommended for virtually all depressed patients who respond to antidepressants, with a longer course of maintenance phase… Expand
Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
TLDR
Relapse risk was reduced by both C-CT and fluoxetine in an enriched randomization sampling only CT responders, suggesting that some higher-risk patients may require alternate longer-term interventions. Expand
Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis
TLDR
Future research that focuses on understanding causal pathways that link childhood maltreatment to dysfunction in the neocortical and limbic pathways that process affective information and facilitate cognitive control might result in more enduring effects of treatments for depression. Expand
Maintenance pharmacotherapy for unipolar depression: focus on efficacy
TLDR
Many evidences are available for an adequate long-term drug treatment of unipolar depression, however, more randomised controlled studies are need to better establish how to manage unipolar patients at high risk of recurrence and to explore the differences in the effectiveness among ADs in the long- term treatment of such patients. Expand
Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
TLDR
The trial evaluates the preventive effects and durability of acute and continuation phase treatments in the largest known sample of CT responders collected worldwide. Expand
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors
TLDR
This is one of the first reports demonstrating a beneficial effect of long-term antidepressant medication on severe relapse rates in naturalistic patients, and may be a proxy marker for treatment resistant and psychotic depression. Expand
First-line pharmacotherapies for depression - what is the best choice?
TLDR
This review examines the antidepressants that are currently used as the initial or "first-line" therapies for major depressive disorder (MDD), and these newer medications may be grouped into three classes: the selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptakes inhibitors, and the norpinephrine-dopamine reptake inhibitor. Expand
Interventions for preventing relapse or recurrence of depression in primary health care settings: A systematic review.
TLDR
There is limited evidence to inform relapse or recurrence prevention strategies specifically in primary care, and none of the three randomized controlled trials included in this review showed a statistically significant superiority of an intervention for the prevention of depression relapse or Recurrence. Expand
Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants
TLDR
Trazodone may be advantageous in patients presenting recurrence of moderate-to-severe depressive symptoms that include sleep problems and/or insomnia and may be particularly useful when benzodiazepines are not recommended. Expand
Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder
TLDR
The hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials supports the hypothesis that an increase in prior antidepressants exposure is associated with a reduced responsiveness to sertraline therapy. Expand
Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications.
TLDR
Current knowledge about the nosology and neurobiological basis of dysthymia and persistent depressive disorder is discussed, emphasising a dimensional perspective based on course for further research, and a tailored, modular approach to accommodate its multifaceted nature is proposed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial.
TLDR
Augmenting treatment as usual with CT resulted in a significant protective effect, which intensified with the number of previous depressive episodes experienced, extending the accumulating evidence that cognitive interventions following remission can be useful in preventing relapse/recurrence in patients with recurrent depression. Expand
Cognitive therapy in relapse prevention in depression.
  • E. Paykel
  • Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
CBT appears to be more on preventing symptom return than on lessening current symptoms, to summate well with continuation and maintenance antidepressant, and not to be due simply to enhanced medication adherence. Expand
Discontinuing Antidepressant Treatment in Major Depression
TLDR
Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates, and differences in relapses off versus on antidepressants fell markedly with longer follow‐up, but gradual discontinuation (dose‐tapering or use of long‐acting agents) did not yield lower relapse rate. Expand
Maintenance treatment of major depression in old age.
TLDR
Patients 70 years of age or older with major depression who had a response to initial treatment with paroxetine and psychotherapy were less likely to have recurrent depression if they received two years of maintenance therapy with parxetine, and monthly maintenance psychotherapy did not prevent recurrent depression. Expand
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
TLDR
Continuing treatment with antidepressants in patients with depressive disorders who have responded to acute treatment reduced the odds of relapse by 70% and seemed to persist for up to 36 months, although most trials were of 12 months' duration, and so the evidence on longer-term treatment requires confirmation. Expand
Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years.
TLDR
In geriatric patients with recurrent major depression, maintenance treatment with nortriptyline or IPT is superior to placebo in preventing or delaying recurrence and combined treatment using both appears to be the optimal clinical strategy in preserving recovery. Expand
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
TLDR
Cognitive therapy has an enduring effect that extends beyond the end of treatment and seems to be as effective as keeping patients on medication. Expand
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
TLDR
Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients. Expand
Fluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
TLDR
In conclusion, fluoxetine at 20 mg/ day was effective and well tolerated for the prophylactic treatment of recurrent unipolar major depression. Expand
Five-year outcome for maintenance therapies in recurrent depression.
TLDR
It is concluded that active imipramine treatment is an effective means of preventing recurrence beyond 3 years and that patients with previous episodes less than 2 1/2 years apart, therefore, merit continued prophylaxis for at least 5 years. Expand
...
1
2
3
4
5
...